Technical Analysis for ESPR - Esperion Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Gapped Up | Strength | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Pocket Pivot | Bullish Swing Setup | -0.97% | |
Spinning Top | Other | -0.97% | |
Lower Bollinger Band Walk | Weakness | -0.97% | |
Wide Bands | Range Expansion | -0.97% | |
Lower Bollinger Band Touch | Weakness | -0.97% | |
Oversold Stochastic | Weakness | -0.97% |
Alert | Time |
---|---|
Possible Inside Day | about 7 hours ago |
Down 3% | about 11 hours ago |
Gap Up Closed | about 11 hours ago |
Gap Up Partially Closed | about 11 hours ago |
Reversed from Up | about 11 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/27/2024
Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of patients with low-density lipoprotein cholesterol and other cardiometabolic risk factors. Its products include ETC-1002, an oral molecule therapy that is in Phase IIa clinical trials to treat lipid and carbohydrate metabolic pathways; ESP41091, which is in pre-clinical trials for type 2 diabetes and obesity treatment; and 4WF, a synthetic therapy that is in pre-clinical trials to reverse the deleterious effects of atherosclerosis. The company is based in Plymouth, Michigan.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Diabetes Lipid Obesity Cardiology Cholesterol Lipoprotein Gabaa Receptor Positive Allosteric Modulators Low Density Lipoprotein Atherosclerosis Niacin
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Diabetes Lipid Obesity Cardiology Cholesterol Lipoprotein Gabaa Receptor Positive Allosteric Modulators Low Density Lipoprotein Atherosclerosis Niacin
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.335 |
52 Week Low | 0.7 |
Average Volume | 5,617,213 |
200-Day Moving Average | 1.65 |
50-Day Moving Average | 2.43 |
20-Day Moving Average | 2.40 |
10-Day Moving Average | 2.19 |
Average True Range | 0.21 |
RSI (14) | 37.89 |
ADX | 17.37 |
+DI | 12.87 |
-DI | 19.01 |
Chandelier Exit (Long, 3 ATRs) | 2.39 |
Chandelier Exit (Short, 3 ATRs) | 2.56 |
Upper Bollinger Bands | 2.90 |
Lower Bollinger Band | 1.90 |
Percent B (%b) | 0.15 |
BandWidth | 41.65 |
MACD Line | -0.11 |
MACD Signal Line | -0.06 |
MACD Histogram | -0.0534 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.25 | ||||
Resistance 3 (R3) | 2.26 | 2.19 | 2.22 | ||
Resistance 2 (R2) | 2.19 | 2.14 | 2.19 | 2.21 | |
Resistance 1 (R1) | 2.12 | 2.11 | 2.09 | 2.12 | 2.20 |
Pivot Point | 2.06 | 2.06 | 2.04 | 2.06 | 2.06 |
Support 1 (S1) | 1.99 | 2.01 | 1.96 | 1.98 | 1.90 |
Support 2 (S2) | 1.92 | 1.97 | 1.92 | 1.89 | |
Support 3 (S3) | 1.85 | 1.92 | 1.88 | ||
Support 4 (S4) | 1.85 |